CSC and Supriya Lifesciences Ltd (hereinafter referred to as Supriya)signed Exclusive Agency Agreement in Feb.2015 (hereinafter referred to as Agreement), mutually agreed that CSC take care of API Chlorpheniramine Maleate’s sales in China market as Supriya's sole agency, the validity of agreement is 10 years. At the end of 2017, Supriya cooperated with China other company in private by violating the Agreement, tried to manipulate the price of Chlorpheniramine API in China Market by the way of narrowing the sales channel, which leaded to the price of Chlorpheniramine domestically increased nearly hundred times. Meanwhile, Supriya unilaterally raised the selling price of Chlorpheniramine API to CSC, and requested CSC to coordinate in the price manipulation. Under this background, CSC was forced to end the Agreement.
Later on CSC requested Supriya to pay back the IDL application costs of Chlorpheniramine Maleate that CSC paid on behalf of Supriya for many times, but all ended with failure.
In Oct. 2018, CSC filed a lawsuit against Supriya. One year later, on January 20th 2020, the People's Court of Minhang District, Shanghai made a first instance decision in the case of import and export agency contract dispute between CSC and Supriya, CSC win the lawsuit and Supriya paid nearly 230,000 yuan to CSC.
Right and wrong always have their own place, justice and freedom always live in human's mind!